Home » Stocks » Ardelyx

Ardelyx, Inc. (ARDX)

Stock Price: $5.78 USD 0.14 (2.48%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $5.65 -0.13 (-2.25%) Aug 7, 5:12 PM

Stock Price Chart

Key Info

Market Cap 515.23M
Revenue (ttm) 8.31M
Net Income (ttm) -90.66M
Shares Out 89.06M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $5.78
Previous Close $5.64
Change ($) 0.14
Change (%) 2.48%
Day's Open 5.60
Day's Range 5.53 - 5.87
Day's Volume 568,453
52-Week Range 2.10 - 8.82

More Stats

Market Cap 515.23M
Enterprise Value 364.28M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 89.06M
Float 57.77M
EPS (basic) -1.17
EPS (diluted) -1.17
FCF / Share -0.85
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.44M
Short Ratio 6.84
Short % of Float 8.51%
Beta 1.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 61.99
PB Ratio 2.99
Revenue 8.31M
Operating Income -86.91M
Net Income -90.66M
Free Cash Flow -75.86M
Net Cash 150.96M
Net Cash / Share 1.69
Gross Margin 56.32%
Operating Margin -1,045.63%
Profit Margin -1,090.70%
FCF Margin -912.63%
ROA -30.58%
ROE -84.35%
ROIC -71.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(124.91% upside)
Current: $5.78
Target: 13.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth102.57%-93.79%---24.02%9.32%434.71%-
Gross Profit4.682.1433.60-24.0331.6228.935.41
Operating Income-91.26-90.95-65.12-113-29.39-1.56-2.87-8.81
Net Income-94.94-91.30-64.34-112-29.62-3.21-6.56-9.79
Shares Outstanding64.4856.2247.4440.1222.8910.251.130.86
Earnings Per Share-1.47-1.62-1.36-2.80-1.29-0.31-5.82-11.32
Operating Cash Flow-76.48-70.27-65.19-92.53-71.8413.401.8121.98
Capital Expenditures-0.33-0.31-2.36-4.87-3.45-1.86-0.28-0.13
Free Cash Flow-76.81-70.59-67.55-97.40-75.2911.541.5321.85
Cash & Equivalents24816813420110710734.6233.08
Total Debt54.7049.21------
Net Cash / Debt19311913420110710734.6233.08
Book Value18711613919310960.68-63.48-57.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ardelyx, Inc.
Country United States
Employees 88
CEO Michael G. Raab

Stock Information

Ticker Symbol ARDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARDX
IPO Date June 19, 2014


Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.